RET Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers The NGS-based Oncomine Dx Target Test will help ID patients with advanced RET-driven lung and thyroid cancers who may be eligible for treatment with Eli Lilly's Retevmo. Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access. FDA Approves Thermo Fisher Scientific CDx for Genentech's Gavreto in NSCLC Patients With RET Fusions Thermo Fisher said the assay is the first and, so far, only FDA-approved test of its kind for a targeted treatment for RET fusion-positive NSCLC. Thermo Fisher Scientific, Eli Lilly to Develop CDx for RET Inhibitor The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292. AmoyDx, Premia Partner With Loxo on Genetic Testing for Cancer Therapy AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development. Feb 26, 2019 Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan Feb 21, 2019 Lung-MAP Trial Expands to Include All Advanced NSCLC Patients, Plans Liquid Biopsy Screening Premium Jan 29, 2019 AmoyDx, Sanomics Ink Deal for Multigene Mutation Detection Kit Oct 31, 2018 Lung Cancer Panel From PlexBio Receives CE Mark Apr 10, 2018 Illumina, Loxo Oncology to Develop Pan-Cancer Companion Diagnostic Mar 26, 2014 Exelixis Gains European Cometriq Nod with Note about Low Response in Non-RET Mutated MTC Patients Premium Nov 30, 2011 CHMP Recommends Caprelsa Approval in EU on Condition AstraZeneca Conducts PGx Trial Premium Breaking News Guardant Health Nabs FDA Approval for Liquid Biopsy CDx With Menarini Breast Cancer Drug Top Five Articles on GenomeWeb Last Week: Guardant Health Layoffs, Ultima Genomics Use, More New Products Posted to GenomeWeb: Qiagen, Thermo Fisher, Bionano Genomics, BillionToOne, More People in the News at Illumina Ventures, Element Biosciences, Epigenomics, Exagen, More Genomic Approaches Boost Rare Disease Diagnoses in Middle Eastern Patient Population The Scan Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups. Genome-Wide Analysis Sheds Light on Genetics of ADHD A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder. MicroRNA Cotargeting Linked to Lupus A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus. Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.